JUMP REPORT
SLEEP NUMBER (SNBR)
EARNINGS RELEASE - JULY 15 (AMC)
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.80/share REV: 216.3/M
___________________________________________________________
LAST QTR: EPS: .72/share ACTUAL: 1.36/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: .23/share REV: 375.36/M
____________________________________________________________
FULL YR: EPS: 1.53/Share REV: 1,500/M
____________________________________________________________
BEAT/MISS RECORD: 68% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 34.11, 7.9, 6.7
EXPECTED JUMP MOVE THIS QUARTER: 15%
——–
*** With market volatility at extremes there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before trading.
Links To Latest News and Headlines
A number of stocks fell in the afternoon session after geopolitical tensions spiked following a strict deadline set for Iran.
Retailers are overhauling their operations as technology redefines the shopping experience. Still, demand can be volatile as the industry is exposed to the ups and downs of consumer spending. This has stirred some uncertainty lately as retail stocks have tumbled by 7.9% over the past six months. This drawdown was worse than the S&P 500’s 2.3% fall.
Price targets for Sleep Number are now concentrated in the US$4 to US$5 range, reflecting a reset from earlier views such as US$10 and US$12 toward levels closer to where more recent research sees value. Analysts pairing these lower targets with Neutral ratings are signaling a wait and see stance, looking for clearer evidence that marketing efforts and the new product lineup can support steadier sales and earnings. As you read on, you will see how these shifting targets fit into the broader…
As Sleep Number battles mounting debt and bankruptcy fears, is SNBR stock headed for a complete collapse or a surprise meme-fueled surge?
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Sleep Tech Devices Market size & share revenue was valued at approximately USD 29.30 Billion in 2025 and is expected to reach USD 34.70 Billion in 2026 and is expected to reach around USD 134.60 Billion by 2035, at a CAGR of 18.46% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are ResMed, Koninklijke Phili
StockJumpers analysis and trade plans are uploaded generally 1 HOUR BEFORE MARKETS CLOSE (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
Members who are too busy to manual trade can use Trade Assist. For more information visit here
Avg Daily Volume: 622,224 Market Cap: 1.29B
Sector: None Short Interest: 23.5
Ticker delayed 20 minutes
NOTICE: All material on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.